- Current report filing (8-K)
January 07 2010 - 2:39PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): January 4, 2010
ALSERES PHARMACEUTICALS, INC.
(Exact Name of Registrant as Specified in Charter)
|
|
|
|
|
Delaware
|
|
0-6533
|
|
87-0277826
|
|
|
|
|
|
(State or Other Juris-
diction of Incorporation
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
|
|
|
239 South Street, Hopkinton, Massachusetts
|
|
01748
|
|
|
|
(Address of Principal Executive Offices)
|
|
(Zip Code)
|
Registrants telephone number, including area code: (508) 497-2360
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy
the filing obligation of the registrant under any of the following provisions (
see
General
Instruction A.2. below):
|
|
|
o
|
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
|
o
|
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
|
o
|
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
|
o
|
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
|
|
|
Item 5.02
|
|
Departure of Directors or Certain Officers; Election of Directors; Appointment of
Certain Officers; Compensatory Arrangements of Certain Officers.
|
On January 4, 2010, Alseres Pharmaceuticals, Inc. (the Company) announced that Dr. Mark
Pykett, President and Chief Operating Officer, left the employ of the Company to become Chief
Executive Officer of Talaris Advisors, LLC, a strategic drug development company. In addition to
Dr. Pykett, 5 other senior technical staff from Alseres have joined Talaris. Talaris is focused on
providing companies like Alseres with external support of drug and diagnostic development programs
on variable cost and risk shared bases. Talaris plans to continue to provide on-going technical,
clinical and regulatory support to Alseres for its existing program as needed by Alseres during
2010.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly
caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
|
Alseres Pharmaceuticals, Inc.
|
|
Date: January 7, 2010
|
By:
|
/s/ Kenneth L. Rice, Jr.
|
|
|
|
Kenneth L. Rice, Jr.
|
|
|
|
Executive Vice President,
Finance and Administration and
Chief Financial Officer
|
|
|
-2-
Alseres Pharmaceuticals (CE) (USOTC:ALSE)
Historical Stock Chart
From Jun 2024 to Jul 2024
Alseres Pharmaceuticals (CE) (USOTC:ALSE)
Historical Stock Chart
From Jul 2023 to Jul 2024